A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.


Celiprolol is a third-generation beta-adrenoceptor blocker with selective beta 1-antagonist, partial beta 2-agonist and mild alpha 2-antagonist actions. It seems to be as effective as other beta-blockers in the treatment of hypertension and angina pectoris. beta-Blockers have many cardioprotective effects and have been shown to reduce the morbidity and… (More)


  • Presentations referencing similar topics